4.5 Article

Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene

Journal

BREAST CANCER RESEARCH AND TREATMENT
Volume 161, Issue 3, Pages 597-604

Publisher

SPRINGER
DOI: 10.1007/s10549-016-4058-7

Keywords

ATM; Germline pathogenic variant; Hereditary breast and ovarian cancer; Whole exome sequencing

Categories

Funding

  1. National Centre for Genomic Analysis (CNAG)
  2. Spanish Ministry of Economy and Competitiveness (MINECO) [SAF2014-57680-R]
  3. Spanish Network on Rare Diseases (CIBERER) by the Health Ministry [PI12/00070]
  4. FEDER
  5. BRIDGES Project [634935]
  6. FIS [15/00059]
  7. La-Caixa foundation
  8. Ministry of Science and Innovation of Spain [PTQ-12-05350]

Ask authors/readers for more resources

There is still a considerable percentage of hereditary breast and ovarian cancer (HBOC) cases not explained by BRCA1 and BRCA2 genes. In this report, next-generation sequencing (NGS) techniques were applied to identify novel variants and/or genes involved in HBOC susceptibility. Using whole exome sequencing, we identified a novel germline mutation in the moderate-risk gene ATM (c.5441delT; p.Leu1814Trpfs*14) in a family negative for mutations in BRCA1/2 (BRCAX). A case-control association study was performed to establish its prevalence in Spanish population, in a series of 1477 BRCAX families and 589 controls further screened, and NGS panels were used for ATM mutational screening in a cohort of 392 HBOC Spanish BRCAX families and 350 patients affected with diseases not related to breast cancer. Although the interrogated mutation was not prevalent in case-control association study, a comprehensive mutational analysis of the ATM gene revealed 1.78% prevalence of mutations in the ATM gene in HBOC and 1.94% in breast cancer-only BRCAX families in Spanish population, where data about ATM mutations were very limited. ATM mutation prevalence in Spanish population highlights the importance of considering ATM pathogenic variants linked to breast cancer susceptibility.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available